
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is a well-established and globally recognized contract research organization with a diverse range of services and partnerships within the life sciences industry. Despite potential short-term challenges such as a decline in revenue and impacts from divestitures, the company is investing in technology and maintains a strong internal execution track record, positioning them for long-term growth and success. However, delays in clinical trials due to the ongoing pandemic may hinder their financial standing and reputation, highlighting the importance of the company's focus on growth and investor confidence.
Bears say
Icon is experiencing positive trends and increasing gross bookings, but challenges such as canceled bookings and pricing pressures remain. Their successful biotech investment strategy and partnerships with early-stage companies provide potential for growth, but potential risks such as accounting issues and delays in clinical trials could affect their rating and price target. Lack of disclosures on key performance indicators hinders a more positive outlook, but the company's focus on sustainability is a positive factor.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares